1. ALLA AKTIER
  2. NYHETER
  3. VÄSTRA HAMNEN CORP. FINANCE

Västra Hamnen Corp. Finance

Nyheter Västra Hamnen Corp. Finance Nyheter alla bolag

Xintela: Taking position for the next phase

• Encouraging interim results with XSTEM OA
• EQGen licensing deal signed regarding EQSTEM
• Our fair value amounts to SEK 1.49 per share

During the spring Xintela announced positive interim data from its phase I/IIa study with XSTEM in knee ostoearthritis. The company also signed a license and collaboration agreement wtih EQGen Biomedical regarding EQSTEM. Despite the advances, Xintela's financial situation remains challenging. The company reported cash holdings of MSEK 6.4 by the end of Q1. Most likely, the company will receive proceeds from the warrant TO3, the last exercise period is ongoing. If fully subscribed, TO3 could add MSEK 11. Xintela is also awaiting the upfront fee of MSEK 1 from EQGen.

Our model suggests a fair value of SEK 1.49 per share. The full report is available here.

About Market Focus

The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering.

This is a press release from Västra Hamnen Corporate Finance AB. 
Web: vhcorp.se
Twitter: @vhcorp_se (https://x.com/vhcorp_se)

Datum 2025-06-02, kl 15:20
Källa MFN
Affiliate
Skapa konto direkt med BankID hos Skilling så får du tillgång till tusentals finansmarknader inom valuta, aktier, krypto och mycket mer. Välj bland 1200+ CFD-instrument över 7 tillgångsklasser till konkurrenskraftiga priser. Skilling erbjuder också en kapitalförsäkring.
CFD är komplexa instrument och har en hög risk att förlora pengar snabbt på grund av hävstång. 77% av icke-professionella kunder förlorar pengar när de handlar med CFD med denna leverantör.